Orally administered lenalidomide (CC-5013) is anti-angiogenic in vivo and inhibits endothelial cell migration and Akt phosphorylation in vitro. - Wikidata - awgldk - TriplyDB

Orally administered lenalidomide (CC-5013) is anti-angiogenic in vivo and inhibits endothelial cell migration and Akt phosphorylation in vitro.

Orally administered lenalidomide (CC-5013) is anti-angiogenic in vivo and inhibits endothelial cell migration and Akt phosphorylation in vitro.

http://www.wikidata.org/entity/Q46409873

about

Mechanism of action of lenalidomide in hematological malignancies Biological activity of lenalidomide and its underlying therapeutic effects in multiple myeloma Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma Pomalidomide is nonteratogenic in chicken and zebrafish embryos and nonneurotoxic in vitro Immunomodulatory drugs and active immunotherapy for chronic lymphocytic leukemia Lenalidomide for the treatment of B-cell lymphoma.Emerging drugs for chronic lymphocytic leukaemia.Immunomodulation therapy with lenalidomide in follicular, transformed and diffuse large B cell lymphoma: current data on safety and efficacy The clinical safety of lenalidomide in multiple myeloma and myelodysplastic syndromes.Immunomodulatory agents in myelofibrosis.Update on chronic lymphocytic leukemia: overview of new agents and comparative analysis.Phase I clinical trial of lenalidomide in combination with sorafenib in patients with advanced cancer.Phase I clinical trial of lenalidomide in combination with temsirolimus in patients with advanced cancer.Phase I trial of valproic acid and lenalidomide in patients with advanced cancer.A phase I dose-escalation study of lenalidomide in combination with gemcitabine in patients with advanced pancreatic cancer.Phase I clinical trial of lenalidomide in combination with 5-fluorouracil, leucovorin, and oxaliplatin in patients with advanced cancer.A Phase I/II Trial of Panobinostat in Combination With Lenalidomide in Patients With Relapsed or Refractory Hodgkin Lymphoma.Phase I study of oral lenalidomide in patients with refractory metastatic cancer Effect of lenalidomide therapy on hematopoiesis of patients with myelodysplastic syndrome associated with chromosome 5q deletion.Brain arteriovenous malformation modeling, pathogenesis, and novel therapeutic targets.Lenalidomide in multiple myeloma: an evidence-based review of its role in therapy.A review of the history, properties, and use of the immunomodulatory compound lenalidomide.A critical review of the molecular pathophysiology of lenalidomide sensitivity in 5q - myelodysplastic syndromes.Update on immunomodulatory drugs (IMiDs) in hematologic and solid malignancies.Combination of azacitidine and lenalidomide in myelodysplastic syndromes or acute myeloid leukemia-a wise liaison?Safety, pharmacokinetics, and immunomodulatory effects of lenalidomide in children and adolescents with relapsed/refractory solid tumors or myelodysplastic syndrome: a Children's Oncology Group Phase I Consortium report.Elotuzumab enhances natural killer cell activation and myeloma cell killing through interleukin-2 and TNF-α pathways Kidney dysfunction during lenalidomide treatment for AL amyloidosis.The use of novel agents in the treatment of relapsed and refractory multiple myeloma Anti-tumor activity and signaling events triggered by the isothiocyanates, sulforaphane and phenethyl isothiocyanate, in multiple myeloma Mechanism of immunomodulatory drugs' action in the treatment of multiple myeloma.Lenalidomide in the context of complex karyotype or interrupted treatment: case reviews of del(5q)MDS patients with unexpected responses.Differential angiogenic regulation of experimental colitis.A prospective clinical trial of lenalidomide with topotecan in women with advanced epithelial ovarian carcinoma.Initial testing of lenalidomide by the pediatric preclinical testing program Establishing Rps6 hemizygous mice as a model for studying how ribosomal protein haploinsufficiency impairs erythropoiesis.Combination therapy targeting the tumor microenvironment is effective in a model of human ocular melanoma The tipping point for combination therapy: cancer vaccines with radiation, chemotherapy, or targeted small molecule inhibitors Rationale and design of the German-Speaking Myeloma Multicenter Group (GMMG) trial ReLApsE: a randomized, open, multicenter phase III trial of lenalidomide/dexamethasone versus lenalidomide/dexamethasone plus subsequent autologous stem cell transpla Expression of the cereblon binding protein argonaute 2 plays an important role for multiple myeloma cell growth and survival.

P2860

Q21198872-23869B32-B49E-4228-9553-72200060CA24 Q21285161-C9BF61E8-CCC8-4780-879D-479A46A6C236 Q24605861-886CD285-D843-493D-9907-704C6E70B037 Q24634078-992044B1-A988-4EA8-8181-AA5C5D688411 Q27001318-D75927E4-3020-4991-BB1C-822FD1FFD54E Q30249007-0E650009-50D4-4ED3-AC0F-8A9DF1261109 Q30353154-416B0C32-048A-46A8-A602-E88DC614D495 Q30659342-F120606B-C6AE-4957-AFAB-9073FAF0DE9C Q33398044-DCE6D8EA-148D-4A10-9B83-368029C9C44E Q33401615-E8208DDF-C3E2-482B-8D46-B63790FEAD13 Q33406478-0A179F74-7026-4A76-A93E-1F83AA527FBC Q33408279-0F914786-3204-46C1-81AF-095C3128C187 Q33410022-727B9D56-6EB8-417D-9FE3-F21028457A74 Q33420263-1B3D167C-0401-4585-A5C7-72BFC867E65B Q33421680-E9675443-4091-4ED1-8957-B8B776B89351 Q33429608-1575E2D6-0FA4-45EF-B230-F0BA815C8900 Q33442755-DBE23691-CF5C-4F4A-942C-1E8B97C9C323 Q33600521-E8CB1052-D8AE-4AFE-97E9-6B78FAEE0AD3 Q33707411-167FE670-0843-4B7A-AE12-AD160DCDE39D Q33843008-AAC8DB03-BEDC-4563-8CF8-C5AC448741C2 Q33973877-22BF207C-F93C-4B0B-9473-81644168DCDA Q34173071-A8AB3FF8-01EC-4C9B-967A-0FFDB7D3667F Q34220013-F5DA7A4A-02C6-4500-A982-97F597AC6228 Q34253548-5EEBFD5A-883B-4205-ABC5-AB990A6CAE09 Q34342944-B280AD8F-9FF9-465E-BBF8-FE15684F6A8F Q34666858-D197A8D1-0337-4479-B809-62FB576AE398 Q34807860-3D44E781-1F09-46E8-85C2-B54E7ADE923D Q35025410-5045C3B5-A3F9-46AC-80FE-DA329FE28E2C Q35097319-655A5C34-988D-4337-9F8B-2F028D5479A8 Q35143496-1026A118-889E-47CE-84B2-FEF7D1DF3131 Q35171777-993AA677-6EED-4115-9F22-32C6DB268F8D Q35230041-247D96E5-1FB0-49F9-BC2F-FED89A972F05 Q35569803-99781AA4-BC98-4FC9-A9B3-F49E29F2349E Q35608564-2C7F5257-2CB8-48B1-8149-E4DCD5A12642 Q35861457-0A8BF284-3079-4875-8880-2AB18B4C1272 Q35869411-93EF3245-814D-4C5B-A86F-EF4FE1270E9A Q35928569-DDF73513-4907-41DF-8F32-FF46E2705C7E Q35975387-219A0548-18C9-4F61-AFCC-23BB6829654B Q35999062-A787D640-1911-4A21-90A5-58C30F114409 Q36007765-B3EA2358-9D23-49C7-ACA6-49AA81923F44

P2860

Orally administered lenalidomide (CC-5013) is anti-angiogenic in vivo and inhibits endothelial cell migration and Akt phosphorylation in vitro.

http://www.wikidata.org/entity/Q46409873

description

2005 nî lūn-bûn

@nan

2005年の論文

@ja

2005年学术文章

@wuu

2005年学术文章

@zh

2005年学术文章

@zh-cn

2005年学术文章

@zh-hans

2005年学术文章

@zh-my

2005年学术文章

@zh-sg

2005年學術文章

@yue

2005年學術文章

@zh-hant

name

Orally administered lenalidomi ...... Akt phosphorylation in vitro.

@en

Orally administered lenalidomide

@nl

type

label

Orally administered lenalidomi ...... Akt phosphorylation in vitro.

@en

Orally administered lenalidomide

@nl

prefLabel

Orally administered lenalidomi ...... Akt phosphorylation in vitro.

@en

Orally administered lenalidomide

@nl

P1433

Q46409873-5F08A080-44D2-4614-8BA4-93531E56D503

P1476

Q46409873-CAB3A8CA-6ACB-490B-8CA8-200DBB136A58

P2093

Q46409873-1ECCB59B-AA1C-4036-8BE9-193007D51337

Q46409873-2670806E-F36B-4FFE-947E-1AFB6CFEE7CA

Q46409873-68DA9D6A-41D3-4686-9953-FA7602572580

Q46409873-6E2AC69A-8A17-480C-8D58-84A99BB5744B

Q46409873-7D8B5FE4-F0A2-4AC2-B0D8-4A4E22397294

Q46409873-A58877AA-D40A-47D8-9CF9-86930E191135

Q46409873-B0FB3BB3-50D7-4D4D-B710-1AC55D325D75

Q46409873-C4CE08FF-3975-4774-8D07-5E6BC0019B09

Q46409873-D9F006DC-DD57-4D6D-A5DF-2C5190A9945A

Q46409873-DCDE07D6-CB26-482F-B618-CC7CB3B917D2

P304

Q46409873-BEEBC288-46C2-4987-A64A-439ED975AED8

P31

Q46409873-F71D253A-BE9A-4F16-A8DC-2CD3D7B68EEF

P356

Q46409873-398E7425-CF45-4623-82D7-360E04B44E65

P433

Q46409873-CBCB13F9-AAE6-4B80-968A-CD7F1A8D77FD

P478

Q46409873-2FB8E969-31BC-486D-9518-07166F48A6C8

P50

Q46409873-5ADC6E73-9202-4E08-969A-8BD7D95F07B9

P577

Q46409873-466246F5-3BC7-456B-851D-DA6A24D74844

P698

Q46409873-92961DB8-06E7-446A-B9BC-4429F5084FB2

P921

Q46409873-88548924-DD03-409F-856C-DFAF0DCC3908

P356

J.MVR.2005.01.002

P1433

Microvascular Research

P1476

Orally administered lenalidomi ...... Akt phosphorylation in vitro.

@en

P2093

Angus G Dalgleish

http://www.w3.org/2001/XMLSchema#string

David Stirling

http://www.w3.org/2001/XMLSchema#string

George Muller

http://www.w3.org/2001/XMLSchema#string

J Blake Bartlett

http://www.w3.org/2001/XMLSchema#string

Keith Dredge

http://www.w3.org/2001/XMLSchema#string

Ling Lu

http://www.w3.org/2001/XMLSchema#string

Ling-Hua Zhang

http://www.w3.org/2001/XMLSchema#string

Michael A Shirley

http://www.w3.org/2001/XMLSchema#string

Peter Schafer

http://www.w3.org/2001/XMLSchema#string

Rebecca Horsfall

http://www.w3.org/2001/XMLSchema#string

P304

56-63

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.MVR.2005.01.002

http://www.w3.org/2001/XMLSchema#string

P433

1-2

http://www.w3.org/2001/XMLSchema#string

P478

69

http://www.w3.org/2001/XMLSchema#string

P50

Simon P Robinson

P577

2005-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

15797261

http://www.w3.org/2001/XMLSchema#string

P921

phosphorylation